• Independant law firm

    Independant law firm

  • in intellectual property

    in intellectual property

  • with international scope

    with international scope

  • February 2020

    Cabinet Barny advised Neurochlore on the conclusion of an exclusive license agreement with Hyundai for the development and commercialization of ASD treatment

    Read more

  • October 2018

    Cabinet Barny advised Enterome on the conclusion of a global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease.

    Enterome will receive an upfront payment of $50 million and a commitment from Takeda to make a future equity investment in the Company. Enterome is also eligible to receive up to $640 million for achieving specified clinical development, regulatory and commercial milestones with Enterome's drug candidate EB8018.

    Click here for more information.

    Read more

  • April 2018

    Cabinet Barny advised Domain Therapeutics on the assignment of its intellectual property rights towards Foliglurax in the course of Lundbeck's acquisition of Prexton Therapeutics.

    Read more

  • May 2017

    Cabinet Barny advised ILTOO PHARMA on the conclusion of a license option agreement with Servier for the clinical development and commercialization of the ILT-101 drug candidate for the treatment of autoimmune diseases.

    Click here for more information.

    Read more

  • April 2017

    Cabinet Barny advised Domain Therapeutics on the conclusion of a collaboration agreement with Pfizer.

     

    Click here for more information.

    Read more

  • March 2017

    Cabinet Barny advised Neurochlore on the conclusion of an exclusive license agreement with Servier for the development and commercialization of bumetanide in the field of autism in children in Europe.

    Read more

  • November 2016

    Cabinet Barny advised Enterome on the conclusion of a collaboration agreement with Bristol-Myers Squibb in the field of Immuno-Oncology, focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules.

     

    Click here for more information.

    Read more

  • October 2016

    Cabinet Barny advised Domain Therapeutics on the creation with Medicxi of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.

     

    Click here for more information.

    Read more

  • September 2016

    Cabinet Barny advised Domain Therapeutics on the conclusion of a second licensing and partnership agreement on GPCR biosensor technology with Université de Montréal, the Institute for Research in Immunology and Cancer – Commercialization of Research and McGill University.

     

    Click here for more information.

    Read more

  • JUNE 2016

    Cabinet Barny advised Meiogenix on the conclusion of a collaboration agreement with Lesaffre in the field of industrial yeast strains.

    Click here for more information.

    Read more

  • APRIL 2016

    Cabinet Barny advised Meiogenix on the conclusion of a licence agreement with Bayer, where Meiogenix has granted Bayer a licence on its StiX proprietary technology, in the field of genetic technologies.

    Click here for more information.

    Read more

  • March 2016

    Cabinet Barny advised Peptimimesis on the conclusion of a research partnership agreement with Ipsen in the field of oncology.

    Read more

  • January 7, 2016

    Cabinet Barny advised Enterome on the conclusion of a collaborative research agreement with Johnson & Johnson Innovation for the discovery of novel targets and therapeutics for the treatment of Crohn’s disease.

    http://www.enterome.fr/site/wp-content/uploads/2016/01/PR_Enterome_JJ_EN.pdf

    Read more

  • January 6, 2016

    Cabinet Barny advised Enterome on the conclusion of a collaborative research and development agreement with Takeda, with an exclusive licence option to the benefit of Takeda, to develop therapeutics directed at microbiome targets for the treatment of gastrointestinal disorders.

    http://www.enterome.fr/site/wp-content/uploads/2016/01/PR_Enterome_Takeda_EN.pdf

    Read more

  • July 2015

    Cabinet Barny advised Lysogene on the conclusion of a collaboration agreement with Alcyone Lifesciences for research against Sanfilippo syndrome Type A.

    Read more

    Experience at the service of those who innovate

    Our Independence at the service of pioneers

    Cabinet BARNY is an independent law office which provides a fully integrated service in the field of innovation, especially in life science (pharmacy, biotechnology, biopharmacy, medical devices…).

    Cabinet BARNY is also active in the field of mechanics, in particular with regards to tooling and sports devices. 

    Maître Luc BARNY has founded the practice in 2001 under the “law boutique” model: Cabinet BARNY provides a transversal approach and deals with the different legal issues concerning innovation in a consistent manner. 

    By nature, legal problems call for specific responses. This is even more true in the field of innovation, where the value of innovative companies stems from the specificity of their project.

    Cabinet BARNY has accompanied the creation and development of numerous start-ups and actively supports innovative entrepreneurs. 

    Cabinet BARNY also has a genuine expertise in the prevention and resolution of litigations.

    We guarantee you:

    • A true independence
    • 18 years of experience and expertise in the field of technology transfer
    • Our ability to deal with complex dossiers and the assurance that the objectives are met
    • A dedicated and available senior lawyer 
    • A thorough understanding of business environment, public research and technologies
    • A French/English bilingual practice for contractual and contentious matters
    • The access to a network of internationally renowned lawyers for the acquisition and protection of your rights in the whole world